Validation of a venous thromboembolism risk assessment model in gynecologic oncology

Venous thromboembolism prophylaxis in cancer patients — guidelines focus on surgical patients

“…Similar to general surgery patient population, there are also reports suggesting a high efficacy of intermittent pneumatic compression in patients referred to gynecological cancer surgery [14,143,144]. Research conducted by Maxwell et al related to 211 patients undergoing gynecological cancer surgery compared the results of thromboprophylaxis by the means of LMWH and IPC -in both groups no cases of symptomatic VTE and only 3 cases of asymptomatic ultrasonographically proven proximal DVT cases (in examination performed 3-5 days after surgery) were found [145].…”

Postoperative Thromboembolism in Gynecologic Oncology Patients. Still a Lethal but Preventable Complication

“…This risk stratification model, taking into account independent risk factors, determines four levels of risk for VTE that correlate to the incidence of VTE and recommends the prophylactic measures needed for each level. This model is validated in gynecologic oncology patients [6].…”

“…Optimal prophylaxis should take into account and estimate both risk of VTE and bleeding complications from anticoagulation treatment. Although existing models for risk stratification, such as Caprini score, have important limitations, they should be considered as a guide in individualization of management [6]. In those patients, a combination of an aforementioned pharmacologic and a mechanical agent seems to improve preventive efficacy.…”

Thromboprophylaxis in women undergoing gynecological surgery or assisted reproductive techniques: new advances and challenges

“…It has been reported that approximately 38% of gynecological oncology patients will suffer from perioperative thromboembolic complications without VTE prophylaxis, and PE remains the leading cause of postoperative death among these patients [17,18]. It is due to the fact that patients with active malignancy have additional VTE risk factors such as the malignancy itself, advanced age, vascular compression by a pelvic mass, lengthy surgery, vascular injury, and treatment with chemotherapy, which increases thrombotic risk [19].…”

“…This phenomenon is associated with the fact that VTE prophylaxis is given to most cancer patients only during hospitalization and the treatment is interrupted after discharge due to the risk of bleeding which is more common in cancer patients [17]. Although warfarin remains the mainstay of anticoagulant therapy for VTE treatment, LMWH has been studied extensively and has been adopted as the anticoagulant of choice in the oncology setting [17]. The non vitamin K oral anticoagulants, i.e.…”